Menlo Park, United States
Celeris Therapeutics, founded in 2021, is at the forefront of revolutionizing drug discovery using artificial intelligence. Its proprietary platform, CelerisTx One™, leverages deep learning for the innovative design of PROTACs (proximity-inducing compounds). By focusing on the development of New Chemical Entities that harness endogenous cellular mechanisms, Celeris aims to address the typical inefficiencies in R&D.
Operating from the United States, Celeris is strategically targeting critical unmet needs in CNS and oncology. They are also engaged in collaborative efforts with pharmaceutical and biotech firms to enhance therapeutic solutions. Celeris's commitment to cutting-edge technology positions it as a disruptive force in industries such as AI, Biotechnology, and Life Sciences.
With a total capital commitment of EUR 18 million from notable investors like EIC Fund and Apex Ventures, and a recent €10 million investment from the European Innovation Council on 19 October 2022, Celeris Therapeutics is poised for future growth and innovation in drug development.
